r348
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2012 (NCT01733992)
Timeline
Indications
Mechanism of action
- Tyrosine-protein kinase JAK3INHIBITOR
JAK3 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- r348
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02040623 | Phase 2 | Mar 1, 2014 | Rigel Pharmaceuticals |
| NCT01900249 | Phase 2 | Jul 1, 2013 | Rigel Pharmaceuticals |
| NCT01733992 | Phase 1 | Nov 1, 2012 | Andover Eye Associates, Rigel Pharmaceuticals |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Rigel Pharmaceuticals | For profit | 3 | 3 | 2 | 2012 |
| Andover Eye Associates | Academic/Hospital | 1 | 0 | 1 | 2012 |
2 organizations
Page 1 / 1